What's special about Tonix Pharma and Southern Research's COVID-19 vaccine candidate?

27 June 2020

Tonix Pharmaceuticals (Nasdaq: TNXP) and Southern Research have partnered to create a COVID-19 vaccine based on Tonix’ proprietary horsepox vaccine platform.

The research is part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix’ TNX-1800, which is a live replicating virus vaccine designed to protect against COVID-19. The data will support the interpretation of animal trial results with TNX-1800, which are expected in the fourth quarter of 2020 and subsequent human trials.

Dr Seth Lederman, president and chief executive of Tonix and a former tenured professor at Columbia Medical School, who has made original contributions to immunology and virology, commented: “Tonix’ TNX-1800 is based on a virus that we believe is closely related to Dr Jenner’s first vaccine. Vaccines that descended from Dr Jenner’s vaccine were used to eradicate smallpox globally, the only virus ever successfully eradicated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK